Results 161 to 170 of about 7,263 (276)

Comparison of IV granisetron and IV palonosetron on hemodynamics and sensory and motor block after spinal anesthesia with hyperbaric bupivacaine in patients undergoing abdominal hysterectomy

, 2019
Rajesh Mahajan, Jasmeen Choudhary, Arti Mahajan, Smriti Gulati, Anjali Mehta, Robina Nazir   +5 more
openalex   +1 more source

“A comparison of ondansetron and palonosetron for prevention of post-operative nausea and vomiting in patients undergoing elective abdominal surgeries under general anaesthesia” A randomized double blind study

, 2015
Alpana Arya, Shilpi Jain, Suresh Chandra Dulara, Loveleena Gupta   +3 more
openalex   +1 more source

Application of Box-Behnken design for optimization of A RP-HPLC method for determination of palonosetron and netupitant in their combined dosage form in presence of their impurities

, 2022
Mohamed A. ElHamid, Ehab F. Elkady, Eman A. Mostafa   +2 more
openalex   +2 more sources

Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study. [PDF]

Sci Rep
Cai Y, Luo S, Lin S, Huang X, Wang X, Yang L, Xu X, Weng X.   +7 more
europepmc   +1 more source

Comparative Study of Lidocaine and Palonosetron Pretreatment in Reduction of Propofol Induced Injection Pain

, 2018
Suruchi Ambasta, Swagat Mahapatra
openalex   +1 more source

5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma. [PDF]

EMBO Mol Med
Feng Y, He Y, Zuo R, Gong W, Gao Y, Wang Y, Wang Y, Chen W, Chen L, Luo Y, Yuan D, Chen P, Guo H.   +12 more
europepmc   +1 more source

Prolonged inhibition of 5‐HT₃ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalization

, 2013
Joanne Hothersall, Christopher Moffat, Christopher N. Connolly   +2 more
openalex   +2 more sources

STOP-CINV Study: Safety and Efficacy of IV Akynzeo® (Fosnetupitant 235 mg and Palonosetron 0.25 mg) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Indian Patients. [PDF]

Cureus
Shukla P, Valame S, Nanda S, Shakya NK, Verma AK, Hanji A, Pednekar A, Bhagat S, Patil S, Petare AU, Bhushan S, Barkate H.   +11 more
europepmc   +1 more source

Aprepitant use during chemotherapy and association with survival in women with early breast cancer. [PDF]

J Natl Cancer Inst
Botteri E, Hjorth S, Conforti F, Bagnardi V, Andreassen BK, Støer NC, Bhargava S, Ursin G, Gandini S, Sloan EK, Chang A.   +10 more
europepmc   +1 more source

Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy [PDF]

, 2016

core   +1 more source